New Horizons for the Roles and Association of APE1/Ref-1 and ABCA1 in Atherosclerosis
Open Access
- 1 October 2021
- journal article
- review article
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 14, 5251-5271
Abstract
Atherosclerosis is the leading cause of death worldwide. APE1/Ref-1 and ABCA1 play key roles in the progression of atherosclerosis. APE1/Ref-1 suppresses atherosclerosis via multiple mechanisms, including reducing the IL-6-, TNF-α-, and IL-1β-mediated proinflammatory responses, suppressing ROS-mediated oxidant activity and Bax/Bcl-2-mediated vascular calcification and apoptosis, and reducing LOX-1-mediated cholesterol uptake. However, APE1/Ref-1 also promotes atherosclerosis by increasing the activity of the NK-κB and S1PR1 pathways. APE1/Ref-1 localizes to the nucleus, cytoplasm, and mitochondria and can be secreted from the cell. APE1/Ref-1 localization is dynamically regulated by the disease state and may be responsible for its proatherogenic and antiatherogenic effects. ABCA1 promotes cholesterol efflux and anti-inflammatory responses by binding to apoA-I and regulates apoptotic cell clearance and HSPC proliferation to protect against inflammatory responses. Interestingly, in addition to mediating these functions, ABCA1 promotes the secretion of acetylated APE1/Ref-1 (AcAPE1/Ref-1), a therapeutic target, which protects against atherosclerosis development. The APE1/Ref-1 inhibitor APX3330 is being evaluated in a phase II clinical trial. The LXR agonist LXR-623 (WAY-252623) is an agonist of ABCA1 and the first LXR-targeting compound to be evaluated in clinical trials. In this article, we review the roles of ABCA1 and APE1/Ref-1 in atherosclerosis and focus on new insights into the ABCA1-APE1/Ref-1 axis and its potential as a novel therapeutic target in atherosclerosis.Keywords
This publication has 113 references indexed in Scilit:
- PAPP-A negatively regulates ABCA1, ABCG1 and SR-B1 expression by inhibiting LXRα through the IGF-I-mediated signaling pathwayAtherosclerosis, 2012
- Functional Analysis of Novel Analogues of E3330 That Block the Redox Signaling Activity of the Multifunctional AP Endonuclease/Redox Signaling Enzyme APE1/Ref-1Antioxidants & Redox Signaling, 2011
- Ht31, a Protein Kinase A Anchoring Inhibitor, Induces Robust Cholesterol Efflux and Reverses Macrophage Foam Cell Formation through ATP-binding Cassette Transporter A1Journal of Biological Chemistry, 2011
- Tissue-Specific Liver X Receptor Activation Promotes Macrophage Reverse Cholesterol Transport In VivoArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of LXR‐623, a Novel Liver X‐Receptor Agonist, in Healthy ParticipantsThe Journal of Clinical Pharmacology, 2009
- Transcriptional Regulatory Functions of Mammalian AP-Endonuclease (APE1/Ref-1), an Essential Multifunctional ProteinAntioxidants & Redox Signaling, 2009
- Decreased levels of lipid peroxidation-induced DNA damage in the onset of atherogenesis in apolipoprotein E deficient miceMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2007
- Apurinic/apyrimidinic endonuclease1/redox factor-1 inhibits monocyte adhesion in endothelial cellsCardiovascular Research, 2006
- Molecular interactions between apoE and ABCA1Journal of Lipid Research, 2004
- ATP-binding Cassette Transporter A1 (ABCA1) Functions as a Cholesterol Efflux Regulatory ProteinJournal of Biological Chemistry, 2001